How Arecur works

After successful treatment of an infectious or oncological disease, an exacerbation or recurrence is not excluded.¹ It is important to support the immune system not only after protocol therapy but also during the treatment of precancerous diseases. Immune peptides in the Arecur® drug activate immunity, and as a result, immune cells find and destroy bacteria and viruses. And most importantly, Arecur® neutralizes infected or atypical cells that can become dangerous or malignant.² It is important that Arecur® engages only mature and ready-to-work effectively immune cells - lymphocytes and macrophages, therefore it acts powerfully and safely, without depleting immune system resources (Figure).



Figure. The mechanism of action of the immune peptides of the drug Arecur®: activation of lymphocytes, identification and destruction of dangerous cells, involvement of macrophages to remove toxic residues. 

Arecur® not only strengthens the immune system, but also helps the body to cope with intoxication caused by the death of bacteria and viruses after taking antibiotics. It's simple: activated lymphocyte-defenders destroy the infection, and diligent macrophages dispose the residues.³
In addition, by stimulating the active work of immune cells, Arecur® ensures the synthesis of immunoglobulin proteins that destroy infection and prevent the appearance of dangerous cells in precancerous diseases.² 
Arecur® complements the antitumor effects of protocol chemotherapy, strengthens immunity and, as an accompanying drug, helps the body to cope with the intoxication caused by the death of tumor cells.⁴ This significantly alleviates the general condition of patients and significantly improves their quality of life.⁵


1.    Marzagalli M, Fontana F, Raimondi M, Limonta P. Cancer Stem Cells-Key Players in Tumor Relapse. Cancers (Basel). 2021 Jan 20;13(3):376. doi: 10.3390/cancers13030376. PMID: 33498502; PMCID: PMC7864187.
2.    Kurchenko A et al., Anti-recurrent Immunocorrection in Gynecology Andrology and Proctology. Int J of Immunology. 2020. 8 (1):  1-8.
3.    Zakharenko N  et al. Prospects for the Treatment of Endometriosis: The Effect of Immune Peptides on the Reactivation of Immune Surveillance over Ectopic Endometrial Cells. Journal of Gynecology and Obstetrics. 2020. 8 (5): 148-153.
4.    Litvinenko O. et al.  Breast Cancer Relapse Prevention: Role of Anti-Relapsing Immunocorrection. Cancer Sci Res. 2019; 2(2); 1-6. 
5.    Stoliarova O et al. Study of the Exogenous Peptide Effect on the TGF-β1 Expression-A Risk Factor for the Hepatocellular Carcinoma Recurrence. American Journal of Biomedical and Life Sciences. 2019. 7 (4 ): 73-78.

Download the booklet